Almirall Selects 2nd Dermatology Target in AI Drug Discovery Collaboration with Absci

Almirall Selects 2nd Dermatology Target in AI Drug Discovery Collaboration with Absci

For the first target addressed in the partnership, the two companies reported the successful delivery of AI-designed, functional antibody leads.

Absci, Almirall Expand Up-to-$650M Dermatology AI Collaboration

Absci and Almirall have expanded their 21-month-old artificial intelligence (AI)-based collaboration to develop and commercialize AI-designed therapeutics for chronic and debilitating skin diseases, with the Barcelona, Spain-based drug developer selecting the second of two planned targets for development. The expansion of the collaboration follows the companies successfully generating AI-designed, functional antibody leads against their first ta…

Almirall Selects Second Dermatology Target in AI-Based Antibody Collaboration with Absci

Almirall has identified a second dermatology target as […] The post Almirall Selects Second Dermatology Target in AI-Based Antibody Collaboration with Absci first appeared on GeneOnline News. The post Almirall Selects Second Dermatology Target in AI-Based Antibody Collaboration with Absci appeared first on GeneOnline News.